I love the fall. It’s the perfect balance of weather between the summer’s heat and the winter’s snow. I love wearing layers of clothing, and when the leaves on the trees change their colors it means we’re closer to my favorite holiday, Thanksgiving. I also love the fall because there…
neuromyelitis optica spectrum disorder
People with a genetic makeup that causes them to be more susceptible to COVID-19 are nearly five times as likely to develop neuromyelitis optica spectrum disorder (NMOSD) associated with antibodies against aquaporin-4 (AQP4), a study finds. Evidence for a cause and effect, or causal, link between COVID-19 and NMOSD…
Five years ago, Aug. 28, 2017, began like any other day. I had taken the day off work to run errands, and I got up early to help my youngest daughter, Bella, get ready for school. She had just started fourth grade at a new school and had a long…
Trying something new will always intimidate me. While my head might feel prepared, my body doesn’t always cooperate. This year my husband and I agreed to take in a homestay teenager who is studying dance at the same studio as our young daughter, Sophie. Sydney, our 15-year-old homestay daughter, is…
SB12, Samsung Bioepis’ biosimilar candidate of Soliris (eculizumab), is comparable to the original medication in terms of safety, pharmacological properties, and immunoreactivity profile, according to data from a Phase 1 clinical trial in healthy volunteers. Soliris, by Alexion Pharmaceuticals, is an approved therapy for a number of conditions,…
Recent Posts
- Soliris reduces relapse rates in AQP4-positive NMOSD patients: Study
- The pain of NMOSD nerve sensitivity means more than just a cold shoulder
- Most adults with NMOSD use biologic therapies: Registry study
- Every time I turn to Dr. Google, I get an immune system mystery
- Conventional NMOSD treatment effective in double-negative cases
- Grieving how NMOSD has left me uncomfortable in my own skin
- Enspryng outperforms standard immunosuppressants in NMOSD study
- Slow and steady: I’m ditching big resolutions and easing into a new year
- Late-onset NMOSD responds better to newer, highly effective therapies
- New biomarker may help gauge disease severity in NMOSD